JAMA NOVEMBER 19, 2003

A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease (INVEST)

Carl J. Pepine, George A. Messerli, Richard M. Pratt, et al. (for the INVEST Investigators)

Bottom Line

In patients with hypertension and coronary artery disease, a verapamil-based treatment strategy is as effective as an atenolol-based strategy for reducing the risk of death, nonfatal myocardial infarction, or nonfatal stroke.

Key Findings

1. The primary composite endpoint of all-cause mortality, nonfatal myocardial infarction, or nonfatal stroke occurred in 1,126 patients (9.98%) in the verapamil-based strategy group compared to 1,154 patients (10.20%) in the atenolol-based strategy group (hazard ratio 0.98; 95% CI, 0.90-1.06; P = 0.62).

2. There were no significant differences between groups in individual components of the primary endpoint: death (7.75% vs. 7.90%), nonfatal myocardial infarction (1.34% vs. 1.35%), or nonfatal stroke (1.16% vs. 1.31%).

3. Patients assigned to the verapamil-based strategy had a lower incidence of new-onset diabetes (7.03% vs. 8.23%; P = 0.03).

4. Blood pressure control rates were similar between both groups, with approximately 65% of patients achieving systolic pressure targets (<140 mm Hg or <130 mm Hg for high-risk groups) and 90% achieving diastolic targets.

Study Design

Design

RCT

Open-Label

Sample

22,576

Patients

Duration

2.7 yr

Median

Setting

15 countries

Population Patients aged 50 years or older with hypertension and clinically documented coronary artery disease (stable angina, prior myocardial infarction, or revascularization).

Intervention Calcium antagonist-based strategy (Verapamil SR 240 mg once daily, plus trandolapril and/or hydrochlorothiazide as needed).

Comparator Non-calcium antagonist-based strategy (Atenolol 50 mg once daily, plus hydrochlorothiazide and/or trandolapril as needed).

Outcome Composite of all-cause mortality, nonfatal myocardial infarction, or nonfatal stroke.

Study Limitations

• The study was open-label regarding medication, although event adjudication was blinded.

• New-onset diabetes was a post-hoc analysis and not a prospectively defined primary endpoint.

• The findings may not generalize to other calcium channel blockers, beta-blockers, or other diuretic classes beyond those studied.

• A subgroup of patients with heart failure showed worse outcomes in the verapamil arm, suggesting that verapamil should be used with caution in this population.

Clinical Significance

The trial established that in hypertensive patients with stable coronary artery disease, both a calcium antagonist-based regimen and a beta-blocker-based regimen are equally effective for preventing major cardiovascular events, providing clinicians with flexible therapeutic options based on patient-specific tolerability and comorbidities.

Historical Context

At the time of the trial, there was ongoing debate regarding the safety of calcium antagonists in patients with hypertension and coronary disease, largely driven by previous studies of short-acting agents. INVEST was pivotal in providing large-scale, prospective evidence for the long-term safety and efficacy of a long-acting calcium antagonist (verapamil SR) strategy compared to the traditional 'gold standard' beta-blocker-based care.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What are the primary physiological mechanisms by which a non-dihydropyridine calcium channel blocker (like verapamil) and a beta-blocker (like atenolol) achieve similar therapeutic goals in a patient with coronary artery disease (CAD)?

Key Response

Both drug classes reduce myocardial oxygen demand: verapamil by inhibiting calcium-mediated cardiac contraction and causing peripheral vasodilation (reducing afterload), and atenolol by reducing heart rate and contractility through sympathetic blockade. Both also prolong diastole, which improves coronary perfusion.

Resident

Given the equivalence demonstrated in the INVEST trial, what clinical comorbidities would lead you to favor a verapamil-SR based strategy over an atenolol-based strategy in a patient with hypertension and CAD?

Key Response

Verapamil is preferred in patients with reactive airway disease (COPD/asthma) where beta-blockers might cause bronchospasm, or in patients with symptomatic peripheral vascular disease or diabetes with frequent hypoglycemia, as beta-blockers can mask hypoglycemic symptoms or exacerbate claudication.

Fellow

In the context of the INVEST trial's use of trandolapril as a mandatory add-on for specific patients, how does this study inform the management of 'the hypertensive triad' (CAD, hypertension, and diabetes) compared to the findings of the ALLHAT or HOPE trials?

Key Response

INVEST highlighted that in patients with CAD and DM, the combination of a CCB and an ACE inhibitor (verapamil + trandolapril) was particularly effective. This suggests that the 'strategy' (reaching BP goals with blockade of the RAAS) is more critical for renal and vascular protection in diabetics than the specific initial antihypertensive class.

Attending

How did the INVEST trial challenge the historical 'beta-blocker first' dogma in stable coronary artery disease, and how should this influence the teaching of medical students regarding 'optimal medical therapy' (OMT)?

Key Response

INVEST showed that a calcium antagonist strategy is a safe and effective alternative to beta-blockers for preventing major cardiovascular events in stable CAD. This teaches that while beta-blockers are essential post-MI or in HFrEF, BP control itself is a primary driver of outcomes in stable CAD, allowing for greater flexibility in drug choice based on patient tolerance.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The INVEST trial utilized a PROBE (Prospective, Randomized, Open-label, Blinded Endpoint) design. What are the specific methodological risks of using an open-label design in a non-inferiority trial for hypertension, and how might 'performance bias' influence the results?

Key Response

In open-label trials, clinicians may adjust background medications or titration schedules differently if they know the treatment arm, potentially equalizing blood pressures and masking true differences between drugs (performance bias). In a non-inferiority context, this 'noise' biases the results toward the null, making it easier to claim equivalence.

Journal Editor

The primary outcome of INVEST resulted in a Hazard Ratio of 0.98 with a 95% CI of 0.90-1.06. From an editorial standpoint, was the non-inferiority margin pre-specified appropriately, and does the high rate of medication crossover/add-on therapy limit the 'drug-specific' conclusions of the study?

Key Response

A tough reviewer would note that over 80% of patients in both groups ended up on multi-drug regimens, including ACE inhibitors. This makes it difficult to attribute the results solely to verapamil vs. atenolol; rather, it reflects a 'strategy' comparison where the secondary drugs likely diluted the specific effects of the primary agents.

Guideline Committee

How do the results of the INVEST trial reconcile with the current AHA/ACC guidelines for the management of Stable Ischemic Heart Disease (SIHD), specifically regarding the class of recommendation for non-dihydropyridine calcium channel blockers?

Key Response

INVEST provides high-level evidence (Level A) that non-DHP CCBs can be substituted for beta-blockers when BBs are contraindicated or cause side effects. Current guidelines reflect this by giving CCBs a Class I recommendation for symptom relief in SIHD and acknowledging their equivalence in BP-lowering strategies for event reduction, while maintaining BBs as the preferred agent in the immediate post-MI setting.

Clinical Landscape

Noteworthy Related Trials

2002

ALLHAT Trial

n = 33,357 · JAMA

Tested

Amlodipine, Lisinopril, or Doxazosin

Population

Patients aged 55+ with hypertension and at least one other CHD risk factor

Comparator

Chlorthalidone

Endpoint

Fatal CHD or nonfatal MI

Key result: Thiazide-type diuretics were superior in preventing one or more forms of cardiovascular disease and were less costly.

2002

LIFE Trial

n = 9,193 · Lancet

Tested

Losartan

Population

Hypertensive patients with left ventricular hypertrophy

Comparator

Atenolol

Endpoint

Composite of cardiovascular morbidity and mortality

Key result: Losartan reduced the risk of cardiovascular morbidity and mortality compared to atenolol in hypertensive patients with left ventricular hypertrophy.

2004

CAMELOT Trial

n = 1,991 · JAMA

Tested

Amlodipine

Population

Patients with coronary artery disease and normal blood pressure

Comparator

Enalapril or placebo

Endpoint

Incidence of cardiovascular events

Key result: Amlodipine reduced the rate of cardiovascular events in patients with coronary artery disease and normal blood pressure.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis